Skip to main content
Hansa Biopharma logo

Hansa Biopharma — Investor Relations & Filings

Ticker · HNSA ISIN · SE0002148817 LEI · 549300LLEO25ZJJ3NT91 ST Manufacturing
Open in API
Filings indexed 499 across all filing types
Latest filing 2024-04-02 Earnings Release
Country SE Sweden
Listing ST HNSA

About Hansa Biopharma

https://www.hansabiopharma.com/

Hansa Biopharma is a commercial-stage biopharmaceutical company that develops and commercializes treatments for rare immunologic diseases. The company's core focus is its proprietary antibody-cleaving enzyme technology platform, designed to target and inactivate immunoglobulin G (IgG) antibodies. This approach aims to inhibit harmful IgG-mediated immune responses. Its lead product, imilfidase, is used to enable kidney transplantation in highly sensitized patients who have a low probability of finding a compatible donor. The company is also advancing its enzyme technology to address unmet medical needs in other therapeutic areas, including acute autoimmune diseases, gene therapy, and oncology, where IgG antibodies can be a barrier to treatment or a driver of the disease.

Recent filings

Filing Released Lang Actions
Hansa Biopharma förväntar sig stark försäljningsutveckling under första kvartalet 2024
Earnings Release Classification · 100% confidence The document is explicitly titled "PRESSMEDDELANDE" (Press Release) in Swedish. It provides preliminary, unaudited financial expectations (net sales of 54 MSEK) for the first quarter ending March 31, 2024. Crucially, it states that the company "kommer att publicera resultatet för första kvartalet 2024" (will publish the results for the first quarter of 2024) on April 18, 2024, and invites participation in a conference call. This structure—announcing preliminary results and setting a date for the full report release and associated call—is characteristic of an Earnings Release (ER), which provides key highlights before the comprehensive report (IR) is issued. It is not the full Interim Report (IR) itself, nor is it a transcript (CT) or a formal 10-K. Q1 2024
2024-04-02 Swedish
Hansa Biopharma Expects Strong First Quarter 2024 Sales Performance
Earnings Release Classification · 98% confidence The document is a "PRESS RELEASE" from Hansa Biopharma announcing preliminary, unaudited financial expectations for the First Quarter 2024 (Q1 2024). It provides key figures (revenue SEK 54m, product sales SEK 48m) and compares them to prior periods. Crucially, it states: "The Company will publish Q1 2024 results on April 18, 2024." This indicates the document is an early release of key financial highlights before the full, comprehensive report (which would likely be an IR or MDA) is released. This fits the definition of an Earnings Release (ER), which provides initial announcements of periodical financial results (key highlights only). It is not the full Interim Report (IR) itself, nor is it a generic announcement about the report's publication (RPA), as it contains substantive preliminary results. Q1 2024
2024-04-02 English
Annual Report (ESEF) 2023
Annual Report (ESEF) Classification · 100% confidence FY 2023
2024-03-21 Swedish
Annual Report (ESEF) 2023
Annual Report (ESEF) Classification · 100% confidence FY 2023
2024-03-21 Swedish
Interim / Quarterly Report 2023
Interim / Quarterly Report Classification · 100% confidence The document is a 'Bokslutskommuniké' (Year-end report) for Hansa Biopharma for the period January–December 2023. It contains comprehensive financial statements (income statement, cash flow, balance sheet items), management commentary, operational highlights, and pipeline updates. Since it covers a full fiscal year and includes substantive financial data, it qualifies as an Interim/Quarterly Report (IR) under the provided definitions, as it is the primary financial reporting document for the period. FY 2023
2024-02-02 Swedish
Audit Report / Information 2023
Audit Report / Information Classification · 98% confidence The document is titled 'Year-end report January – December 2023' and contains comprehensive financial summaries for Q4 2023 and FY 2023, including revenue, expenses, loss from operation, and EPS figures, along with extensive business and clinical pipeline updates. This structure is characteristic of a full annual financial report, which corresponds to the 10-K filing type, even though the text itself might be a press release version of the annual report data. Given the depth of the financial tables covering the full fiscal year (FY 2023) and the explicit mention of 'Year-end report', it is classified as an Annual Report (10-K) rather than just an Earnings Release (ER) or a Report Publication Announcement (RPA). The document length is substantial (over 86k characters), confirming it is not a brief announcement. FY 2023
2024-02-02 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.